Date: 2017-07-18
Type of information: Private placement
Company: Amicus Therapeutics (USA - NJ)
Investors:
Amount: $258.8 million
Funding type: private placement
Planned used:
- Amicus Therapeutics expects to use the net proceeds of the offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for ATB200, the continued clinical development of its product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes, which may include working capital, capital expenditures, the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property, the acquisition of assets or businesses that are complementary to the company's existing business and general and administrative expenses.
Others:
- • On July 18, 2017, Amicus Therapeutics announced the closing of its previously announced offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,755,102 shares of common stock. As a result, the Company issued a total of 21,122,449 shares in the offering at a price of $12.25 per share.
- The gross proceeds from the offering to Amicus are expected to be $258.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus.
- • On July 12, 2017, Amicus Therapeutics announced the pricing of an underwritten offering of 18,367,347 shares of its common stock at $12.25 per share. The gross proceeds from the offering to Amicus are expected to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,755,102 shares of its common stock. The offering is expected to close on July 18, 2017, subject to customary closing conditions.
- • On July 12, 2017, Amicus Therapeutics announced it has commenced a $225 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint book-running managers and BofA Merrill Lynch and Cowen are acting as co-lead managers for the proposed offering.
Therapeutic area: Rare diseases - Genetic diseases
Is general: Yes
